PDE4B Antibody [A23H17] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
WB1:1000 IP1:150

Application
WB, IP

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
90 kDa

Datasheet & SDS

Biological Description

Specificity
PDE4B Antibody [A23H17] detects endogenous levels of total PDE4B protein.

Clone
A23H17

Synonym(s)
3',5'-cyclic-AMP phosphodiesterase 4B, DPDE4, PDE32, cAMP-specific phosphodiesterase 4B, PDE4B, DPDE4

Background
PDE4B is a cAMP‑specific phosphodiesterase of the PDE4 family that hydrolyzes 3′,5′‑cAMP to AMP and sets local cAMP levels in multiple immune and neural cell types, placing it as a key negative regulator of cAMP‑dependent signaling. The protein contains the conserved catalytic core of class I PDEs, with metal‑binding His and Asp residues forming the active site that coordinates divalent cations and positions cAMP for nucleophilic attack, and N‑terminal regulatory regions that target PDE4B isoforms to defined subcellular compartments and scaffold complexes. In dendritic cells and monocytes, PDE4B is a predominant cAMP‑degrading enzyme, and its activity limits cAMP accumulation after receptor stimulation, thereby controlling the amplitude and duration of PKA‑ and EPAC‑dependent phosphorylation events that influence NF‑κB, CREB, and other transcription factors. By shaping these cAMP gradients, PDE4B regulates production of inflammatory cytokines such as TNF‑α, IL‑6, and IL‑1β, affects expression of costimulatory molecules, and modulates the balance between pro‑ and anti‑inflammatory programs during responses to bacterial lipopolysaccharide and other stimuli. In cardiac myocytes, PDE4B localizes to a sarcolemmal compartment associated with β1‑adrenergic receptors, and its catalytic activity forms part of a local negative feedback loop that constrains cAMP signals generated by β1‑adrenergic stimulation, thereby tuning PKA phosphorylation of nearby substrates that regulate calcium handling and contractility. Genetic deletion or pharmacologic inhibition of PDE4B in this compartment leads to enhanced β1‑adrenergic cAMP responses and altered phosphorylation of proteins linked to excitation–contraction coupling.

Background

PDE4B is a cAMP‑specific phosphodiesterase of the PDE4 family that hydrolyzes 3′,5′‑cAMP to AMP and sets local cAMP levels in multiple immune and neural cell types, placing it as a key negative regulator of cAMP‑dependent signaling. The protein contains the conserved catalytic core of class I PDEs, with metal‑binding His and Asp residues forming the active site that coordinates divalent cations and positions cAMP for nucleophilic attack, and N‑terminal regulatory regions that target PDE4B isoforms to defined subcellular compartments and scaffold complexes. In dendritic cells and monocytes, PDE4B is a predominant cAMP‑degrading enzyme, and its activity limits cAMP accumulation after receptor stimulation, thereby controlling the amplitude and duration of PKA‑ and EPAC‑dependent phosphorylation events that influence NF‑κB, CREB, and other transcription factors. By shaping these cAMP gradients, PDE4B regulates production of inflammatory cytokines such as TNF‑α, IL‑6, and IL‑1β, affects expression of costimulatory molecules, and modulates the balance between pro‑ and anti‑inflammatory programs during responses to bacterial lipopolysaccharide and other stimuli. In cardiac myocytes, PDE4B localizes to a sarcolemmal compartment associated with β1‑adrenergic receptors, and its catalytic activity forms part of a local negative feedback loop that constrains cAMP signals generated by β1‑adrenergic stimulation, thereby tuning PKA phosphorylation of nearby substrates that regulate calcium handling and contractility. Genetic deletion or pharmacologic inhibition of PDE4B in this compartment leads to enhanced β1‑adrenergic cAMP responses and altered phosphorylation of proteins linked to excitation–contraction coupling.

References
https://pubmed.ncbi.nlm.nih.gov/35387344/ https://pubmed.ncbi.nlm.nih.gov/36278172/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%